SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following segments: Walmart U.S., Walmart International, and Sam's Club U.S. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club U.S. segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is facing significant selling pressure after reporting its slowest U.S. comparable sales growth in six years, sparking broader concerns among investors about the resilience of the everyday consumer. While the community is debating whether this pullback represents an attractive long-term entry point or a sign of deeper economic weakness, many are closely watching the company’s strategic pivot toward high-margin advertising and digital services.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF (VTI) remains a central focus as investors grapple with the broader market's heavy reliance on a handful of large-cap tech stocks and ongoing economic uncertainty. The community is actively debating the sustainability of current AI-driven valuations and broader infrastructure bottlenecks, with many viewing VTI as a critical defensive anchor amidst ongoing volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is seeing significant bullish momentum as the community monitors its recovery from recent security concerns and technical breakouts, with many traders drawing parallels to Bitcoin's early growth. Investors are closely tracking key resistance levels, fueled by speculation surrounding a potential ETF catalyst and the active accumulation strategies of major stakeholders.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is seeing increased attention as investors closely track institutional accumulation and key clinical trial catalysts within the sector, with community discourse centered on potential partnership and buyout activity for specific biotech holdings. Market participants are navigating sector-wide volatility by evaluating the relative strength of individual companies against broader index movements and upcoming FDA decision dates.

Sharplink, Inc. is an institutional-grade Ethereum treasury platform that provides public market investors with exposure to Ether. It operates through the following segments: ETH Treasury Management and Affiliate Marketing. The ETH Treasury Management segment focuses on the accumulation and active management of ETH as a long-term treasury asset. The Affiliate Marketing segment focuses on performance-based customer acquisition services for sportsbooks and online casino gaming operators worldwide. The company was founded in 2019 and is headquartered in Miami, FL.

Sharplink Inc.

SharpLink Gaming Ltd

SharpLink Gaming is trending as community discussions focus on its massive Ethereum treasury and the potential for a significant price recovery if regulatory clarity passes and ETH continues its rally. Investors are actively debating the stock's deep discount to net asset value, with many monitoring institutional buying patterns and long-dated call options as indicators of a possible turnaround.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is attracting investor interest as the community highlights its potential as a sovereign, AI-integrated cloud infrastructure that differentiates itself from typical blockchain-focused projects. While some users express frustration with recent price action, proponents remain focused on long-term adoption through developments like Cloud Engines and increased on-chain activity.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending following the launch of its v5.0.0 mainnet upgrade, which introduces features like post-quantum account support, while community members actively debate its long-term potential versus concerns about historical price performance and supply dilution.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as investors show renewed optimism, fueled by broader crypto market momentum and persistent speculation surrounding potential future ties to Elon Musk's companies. The community remains deeply divided, with many long-term holders actively calling for a push toward the one-dollar milestone while others trade based on technical indicators and short-term volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Investors are closely watching for potential Phase 3 clinical trial results for MoonLake's psoriatic arthritis treatment as the company faces a critical reporting deadline and speculation regarding its strategic path forward. Sentiment remains split between long-term optimism over the pipeline's potential and frustration with management's communication style and recent dilution activities.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as investors weigh persistent geopolitical tensions in the Middle East against cooling inflation data, while the broader market faces debate over whether high AI capital expenditures can justify current valuations. Community sentiment is deeply polarized, with active discussions focusing on the sustainability of the AI bubble, the impact of rising bond yields, and the credibility of U.S. economic policy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HALO Stock Rises 36% in a Month: Here's What You Should Know

Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win

Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?

Equity

Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial 

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.


AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

$RGEN Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.09 down -65.38% YoY
• Reported revenue of $204.13M up 11.93% YoY
• Repligen Corporation raised its full year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted earnings per share guidance to $2.03-$2.09, based on expectations for the company's existing business.

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen Corp.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info